ËùÔÚÀ¸Ä¿£º½¡¿µÐÂÎÅ
¡ªÖйú´ó½Ê׸öÒÔ¸Î×é֯ѧÆÀ¼ÛÁÆЧµÄ¹ú¼Ê×¢²áRCTÁÙ´²Ñо¿VENS³É¹û·¢²¼
È«ÇòÊ׸öÒÔÖйú´ó½֬·¾¸Î»¼ÕßΪ¶ÔÏóµÄ¹ú¼Ê×¢²áRCTÁÙ´²Ñо¿ÏîÄ¿VENSÔÚ¾©·¢²¼³É¹û¡£Êý¾ÝÏÔʾ,¿Ú·þÖеȼÁÁ¿ÌìÈ»ÐÍάÉúËØEÊÇÕë¶ÔÖйú·Ç¾Æ¾«ÐÔÖ¬·¾ÐÔ¸ÎÑ×(NASH)»¼Õß°²È«ÓÐЧµÄ»ù´¡ÖÎÁÆÊֶΡ£
2022Äê8ÔÂ21ÈÕ,ÖÐÁª¸Î½¡¿µ´Ù½øÖÐÐÄÖ÷°ìµÄ¡°Òæ·»¤¸Î ·Üé®Ñï·«¡±Ö¬·¾¸ÎѧÊõ½»Á÷»áÉÏ,±±¾©´óѧҽѧ²¿×¯»ÔԺʿ¡¢º¼ÖÝʦ·¶´óѧÉÐÓÀ·áԺʿ,ÊÀ½çÎÀÉú×é֯פ»ª´ú±í´¦³ÂÖÙµ¤²©Ê¿,Öйú¼²¿ØÖÐÐÄÂý²¡¹ÜÀíÖÐÐÄÎâ¾²Ö÷ÈÎ,VENSÏîÄ¿Ö÷ÑÐר¼Ò¡¢ÖлªÒ½Ñ§»á¸Î²¡Ñ§·Ö»áÖ¬·¾¸ÎÓë¾Æ¾«¸Îѧ×éίԱʩ¾üƽ½ÌÊÚ,ÒÔ¼°À´×ÔÈ«¹ú¸Î²¡Âý²¡ÁìÓòר¼Ò¹²Í¬¼ûÖ¤ÁËÕâһѧÊõ³É¹ûµÄ·¢²¼¡£
ÖлªÒ½Ñ§»á¸Î²¡Ñ§·Ö»áÃûÓþÖ÷ÈÎίԱ¡¢Ö¬·¾¸ÎÓë¾Æ¾«¸Îѧ×é×鳤κÀ´½ÌÊÚ±íʾ,VENSÑо¿Ê״λñµÃÌìȻάÉúËØEÖÎÁÆÖйúÖ¬·¾ÐÔ¸ÎÑ×ÈËȺµÄÁÙ´²ÊÔÑéÊý¾Ý,Æä³É¹û¾ßÓÐÐÐÒµÀï³Ì±®ÒâÒå,½«°ïÖúÎÒ¹úÖ¬·¾¸ÎÕïÖÎÂõÉÏÐĄ̂½×¡£ÔÚÁÙ´²ÉÏ,µ±»¼Õß´ÓÖ¬·¾ÐԸβ¡½øչΪ֬·¾ÐÔ¸ÎÑ×(NASH)ʱ,¿É²ÉÓÃÌìȻάE½øÐÐÖÎÁÆ¡£µ±È»,Ö¬·¾¸ÎµÄËùÓÐÖÎÁÆÊÖ¶Î,¼õÖصÈÉú»î·½Ê½¸ÉÔ¤¶¼ÊǷdz£±ØÒªµÄ¡£
VENS(Vitamin E Versus Placebo for the Treatment of Non Diabetic Patients With Nonalcoholic teatohepatitis)ÊÇÒ»Ïî¹ØÓÚάÉúËØEÖÎÁÆ·ÇÌÇÄò²¡·Ç¾Æ¾«ÐÔÖ¬·¾ÐÔ¸ÎÑ׶ÔÕÕ°²Î¿¼ÁµÄÈ«¹ú¶àÖÐÐÄ¡¢´óÑù±¾Ëæ»ú˫äÁÙ´²Ñо¿,¿¼²ìÊÜÊÔÕß¾ÌìȻάÉúËØE½ºÄÒÖÎÁƺóµÄ¸Î×é֯ѧ¸ÄÉÆÂÊ¡£
ÖлªÒ½Ñ§»á¸Î²¡Ñ§·Ö»áÖ¬·¾¸ÎÓë¾Æ¾«¸Îѧ×éίԱ¡¢º¼ÖÝʦ·¶´óѧ¸½ÊôÒ½Ôº¸±Ôº³¤Ê©¾üƽ½ÌÊÚǣͷ·¢ÆðVENSÑо¿,ÓëÈ«¹ú¶«ÄÏÎ÷±±15¼ÒÑо¿ÖÐÐĵÄÍõ±þÔª½ÌÊÚ¡¢³ØÏþÁá½ÌÊÚ¡¢Ê¢»ÛƼ½ÌÊÚ¡¢ÑîÓÀ·å½ÌÊÚ¡¢Ö£Ã÷»ª½ÌÊڵȹúÄÚ¶¥¼¶×¨¼Ò½ÌÊÚÐͬ×÷Õ½,Ö¥¼Ó¸ç´óѧФÊéÔ¨½ÌÊÚ¡¢½â·Å¾ü×ÜÒ½ÔºµÚÎåҽѧÖÐÐÄÕÔ¾°Ã÷½ÌÊÚ¡¢º¼Ê¦´ó¸½ÊôÒ½ÔºÑîÎľý½ÌÊڵȹú¼Ê¹úÄÚÖªÃûµÄÖ¬·¾¸Î²¡Àíר¼Ò¼¯ÖÐÔÄƬ,²ÉÓùú¼Ê×îв¡ÀíÆÀ¼Û·½Ê½ÆÀ¹ÀÁÆЧ¡£
ÕâÒ»ÀúʱÎåÄêµÄ¶àѧ¿ÆÑÖ¤Ñо¿ÏîÄ¿Èë×鲻ͬÃñ×åÊÜÊÔÕß124Àý,Ò©Îï×éÑ¡ÔñÁ˹úÄÚ¾ø´ó¶àÊý¹«Á¢Ò½ÔºÒÑÔÚʹÓõÄÌìÈ»ÐÍάÉúËØE(Õã½Ò½Ò©,À´Òæ ®),ÒÔÖеȼÁÁ¿300mg/Ìì,³ÖÐø¿Ú·þÖÎÁÆ96ÖÜ,¹Û²ìËæ·Ã24ÖÜ¡£Êý¾ÝÏÔʾ,¾»î¼ì֤ʵµÄNASH»¼ÕßÖÎÁÆ×é¡¢°²Î¿¼Á¶ÔÕÕ×éµÄ¸Î×é֯ѧ¸ÄÉÆÓÐЧÂÊ·Ö±ðΪ43.59% ¡¢23.53%, P=0.0436,Á½×é¾ßÓÐÏÔÖøÐÔ²îÒì,ʵÑéÈ«³Ìδ³öÏÖÓëÒ©ÎïÏÔÖøÏà¹ØµÄ°²È«ÐÔ±¨¸æ¡£¾Ý´ËµÃ³ö½áÂÛ:¿Ú·þÖеȼÁÁ¿ÌìÈ»ÐÍάÉúËØEÊÇÕë¶ÔÖйúNASH»¼Õß°²È«ÓÐЧµÄ»ù´¡ÖÎÁÆÊֶΡ£
½üÄêÀ´µÄÁ÷Ðв¡Ñ§Êý¾ÝÏÔʾ,·Ç¾Æ¾«ÐÔÖ¬·¾ÐԸβ¡(NAFLD,¼ò³Æ¡°Ö¬·¾¸Î¡±)ÒѳÉΪÎÒ¹úî¾»¼ÈËÊýµÚÒ»µÄÂýÐԸβ¡,Öйú´ó½µØÇø»¼²¡Âʸߴï30%,×ÜÈËÊý³¬3ÒÚ¡£Èç²»¼°Ê±¸ÉÔ¤,ÎÒ¹ú½«ÓдóÁ¿ÈËȺ´ÓÔçÆÚµ¥´¿Ö¬·¾¸Î½øÕ¹,³ÉΪ·Ç¾Æ¾«ÐÔÖ¬·¾ÐÔ¸ÎÑ×(NASH),ÉõÖÁÏò¸ÎÏËά»¯¡¢¸ÎÓ²»¯¡¢¸Î°©·¢Õ¹,¸øÉç»á¼ÒÍ¥¸öÈËÔì³É³ÁÖØÒ½ÁƸºµ£¡£Ä¿Ç°,ÎÒ¹úNASH»¼ÕßÊýÁ¿ÒÑÍ»ÆÆ3300Íò¡£
½üÊ®ÄêÀ´,¹ú¼ÊÉÏÓëÖ¬·¾¸ÎÏà¹ØµÄÁÙ´²ÊÔÑé·çÆðÔÆÓ¿,µ«Ä¿Ç°ÊÀ½çÉÏÉÐδÓÐÈκÎÒ»¿îÒ©Îï±»Åú×¼ÉÏÊÐÓÃÓÚÖÎÁÆNASH¡£²ÉÓÃÌìÈ»ÐÍάÉúËØEÖÎÁÆNASH»¼ÕßÊǹú¼ÊѧÊõ½çÈϿɵķ½·¨¡£
ÀýÈç,2010Ä꡶ÐÂÓ¢¸ñÀ¼Ò½Ñ§¡·ÔÓÖ¾·¢±íµÄPIVENSÑо¿ÏÔʾ,ʹÓÃÈÕÖÎÁƼÁÁ¿Îª800IU(¼´534mg)µÄÌìÈ»ÐÍάÉúËØE¿ÉÓÐЧÖÎÁƾ»î¼ì֤ʵµÄ·ÇÌÇÄò²¡NASH»¼Õß¡£ÕâÒ»ÖøÃûÑо¿ºÍÁíÒ»ÏîTONICÊÔÑé½á¹û¾ùÖ¤Ã÷ÁËάÉúËØEÔÚÖÎÁÆNASHÑ×Ö¢ÉϵÄÁÆЧȷÇÐ,±»ÃÀ¹ú¸Î²¡Ñ§»á(AASLD)¡¢Å·ÖÞ¸ÎÔàÑо¿Ñ§»á(EASL)¡¢Öлª¸Î²¡Ñ§»áºÍÖлªÄÚ·ÖÃÚѧ»áµÈ¶à¸öȨÍþÖ¸ÄϺ͹²Ê¶×÷ΪһÀàA¼¶Ö¤¾ÝÍƼö¡£µ«ÊÇ,ÓÉÓÚÈËȺÖÖ×åºÍÉú»î·½Ê½´æÔÚ¾Þ´ó²îÒì,¹úÍâÊý¾Ý¶ÔÓÚÎÒ¹ú»¼Õß½è¼øÒâÒåÓÐÏÞ,Ïà¹Ø¸øÒ©·½Ê½ºÍÖÎÁƼÁÁ¿ÊÇ·ñÊÊÓÃÖйúÈËȺ,²¢Î´µÃµ½Êý¾ÝÑéÖ¤¡£
ΪÁË̽Ë÷ÑéÖ¤ÊÊÓÃÓÚÖйúNASH»¼ÕßµÄÁÙ´²½â¾ö·½°¸,VENSÏîĿѧÊõÍŶÓÔÚPIVENSÑо¿»ù´¡ÉÏ,ÓÅ»¯Éè¼ÆÁË¡°¿Ú·þÖеȼÁÁ¿ÌìÈ»ÐÍάÉúËØEÖÎÁÆÖйúNASH»¼Õß¡±µÄÑо¿,ÊÇÖйú´ó½Ê׸öÒÔ¡°Ç°ºóÁ½´Î¸Î»î¼ì¡±×÷ΪÆÀ¼ÛÊֶεÄRCTʵÑé,²¢½øÐйú¼Ê×¢²á,ÔÚ¹ú¼ÊÉÏÊ״λñµÃÁËÕë¶ÔÖйú´ó½ÈËȺµÄÑÖ¤Ö¤¾Ý¡£
VENS³É¹û¶ÔÓÚÖ¸µ¼Ò½ÉúÕïÁÆÖйúNASH»¼ÕßÒâÒåÖØ´ó¡£ÓëPIVENSÁÙ´²ÊÔÑé(Èë×黼Õß¾ùΪŷÃÀÈËÖÖ)²ÉÓø߼ÁÁ¿(534mg/Ìì)ÌìȻάEÏà±È,VENSÑéÖ¤ÁËÖмÁÁ¿(300mg/Ìì)µÄÌìȻάE¿É×÷ΪÖÎÁÆNASHµÄ»ù´¡ÖÎÁÆÓÃÒ©ÇÒ°²È«ÐԼѡ£ÔÚ¿Ú·þÌìȻάE×é,NASH»¼ÕßµÄÑ×Ö¢ÏÔÖø¸ÄÉÆ,ÉõÖÁ¸ÎÏËά»¯Ò²»ñµÃÁËÒ»¶¨³Ì¶È¸ÄÉÆ¡£
Óë»áר¼Ò±íʾ,ÆÚ´ýNASH³É¹û°ïÖúÖйú¸Î²¡Ò½Éú¡¢Ö¬·¾¸Î»¼Õ߸üºÃÓ¦¶ÔÖ¬·¾ÐÔ¸ÎÑ×ÕâÒ»¹²Í¬µÐÈË,¼°Ê±¼ì²â¡¢¹æ·¶ÖÎÁÆ¡¢¶¨ÆÚËæ·Ã,¹²Í¬Íƽø½¨É轡¿µÖйú¡£
VENSÏîÄ¿15¼ÒÑо¿ÖÐÐĺÍÈ«¹úÏà¹ØÒ½ÁÆ»ú¹¹µÄ¸Î²¡Âý²¡×¨¼Ò³öϯ»î¶¯¡£·¶½¨¸ß¡¢Ô¬Æ½¸ê¡¢Ð¤ÊéÔ¨¡¢ÈÄ»Ûçø¡¢Àî½Ü¡¢ÕÔ¾°Ã÷¡¢¶¡»Ý¹ú¡¢Àî漡¢ÆîСÁú¡¢·â²¨¡¢Õž§¡¢Ð»ö©¡¢À¡¢ÐÁÓÀÄþ¡¢Ð쾩º¼µÈר¼Ò×öѧÊõ±¨¸æ»òÖ÷³Ö²ÎÓëÏà¹Ø»·½Ú¡£
¡¸1¡¹ ÊÀ½çÎÀÉú×éÖ¯¡¶½ØÖÁ2030ÄêÖйúÂýÐÔ¸ÎÑ×ËÀÍöÈËÊý¿É¸ß´ïһǧÍò:ÐèÒª½ô¼±Ðж¯,ÖÕÖ¹¡°ÎÞÉùµÄÒßÇ顱¡·
¡¸2¡¹ Sanyal AJ,Chalasani NP,et al.Pioglitazone, Vitamin E, or Placebo for Nonalcoholic Steatohepatitis.N Engl J Med,2010,362(18):1675 1685.
¡¸3¡¹ Chalasani N,et al.The diagnosis and management of non-alcoholic fatty liver disease:practice guideline by the American Gastroenterological Association, American Association for the Study of Liver Diseases, and American College of Gastroenterology.Hepatology,2012,55(6):2005-2023.
¡¸4¡¹ Chalasani NP,et al.Pioglitazone versus vitamin E versus placebo for the treatment of non-diabetic patients with non-alcoholic steatohepatitis:PIVENS trial design.Con Clin Trials,2009,30(1).
¡¸5¡¹ Haptoglobin Genotype and VitaminE Versus Placebo for the Treatment of Nondiabetic Patients with Nonalcoholic Steatohepatitis in China: VENS trial design. Adv Ther. 2018 Feb 6.35:218 231